Research progress of radiolabeled bombesin drugs targeting GRPR in the diagnosis and treatment of prostate cancer
10.3760/cma.j.cn321828-20230310-00055
- VernacularTitle:靶向GRPR的放射性蛙皮素药物在前列腺癌诊疗中的研究进展
- Author:
Haohui SONG
1
;
Mengxin XU
;
Xuqian MA
;
Jie CAI
;
Chao HE
;
Binglin LIU
;
Qi SU
;
Zhibo LIU
Author Information
1. 苏州博锐创合医药有限公司，苏州 215011
- Keywords:
Prostatic neoplasms;
Receptors, bombesin;
Prostate-specific membrane antigen;
Trends
- From:
Chinese Journal of Nuclear Medicine and Molecular Imaging
2024;44(12):764-768
- CountryChina
- Language:Chinese
-
Abstract:
Prostate cancer is the most common cancer among men and the fifth leading cause of cancer-related death among men worldwide. Gastrin-releasing peptide receptor (GRPR) is an important complementary target of prostate specific membrane antigen (PSMA) and a key target for prostate cancer diagnosis and treatment. Radionuclide labeled bombesin (BBN) analogues can accurately target overexpressed GRPR in tumor cells, thus providing early diagnosis and treatment of prostate cancer. In this review, we focus on the studies of 99Tc m, 111In, 68Ga, 64Cu, 18F, and 177Lu nuclide-labeled BBN analogues for diagnosis and peptide receptor radionuclide therapy.
